Conformational complexity of G-protein-coupled receptors

Trends in Pharmacological Sciences

Volumn 28, Issue 8, 2007, Pages 397-406

  Kobilka, Brian K ^a   Deupi, Xavier ^b  

^a STANFORD UNIVERSITY   (United States)

^b Department of Psychiatry and Forensic Medicine   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; RHODOPSIN;

PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW;

ADRENERGIC BETA-AGONISTS; BINDING SITES; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34447633368     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.06.003     Document Type: Review

References (40)

1. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by β-arrestins. Science 308 (2005) 512-517
2. Luttrell L.M., and Lefkowitz R.J. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115 (2002) 455-465
3. Azzi M., et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11406-11411
4. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24 (2003) 346-354
5. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1 (2002) 103-110
6. Frauenfelder H., et al. The energy landscapes and motions of proteins. Science 254 (1991) 1598-1603
7. Kudo M., et al. Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J. Biol. Chem. 271 (1996) 22470-22478
8. Sharma S., and Sharma S.C. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J. Exp. Biol. 35 (1997) 1025-1031
9. Nie J., and Lewis D.L. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci. 21 (2001) 8758-8764
10. Parnot C., et al. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol. Metab. 13 (2002) 336-343
11. Gether U., et al. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J. Biol. Chem. 272 (1997) 2587-2590
12. Kobilka B.K., et al. Chimeric α2,β2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 240 (1988) 1310-1316
13. Schoneberg T., et al. Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor. J. Biol. Chem. 270 (1995) 18000-18006
14. +, and 5-amino-substituted amiloride analogs. J. Biol. Chem. 265 (1990) 17318-17322
15. Palczewski K., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289 (2000) 739-745
16. Ballesteros J.A., and Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. Meth. Neurosci. 25 (1995) 366-428
17. Kim J.M., et al. Structure and function in rhodopsin: rhodopsin mutants with a neutral amino acid at E134 have a partially activated conformation in the dark state. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14273-14278
18. Arnis S., et al. A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J. Biol. Chem. 269 (1994) 23879-23881
19. 2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol. Pharmacol. 56 (1999) 175-184
20. 2 receptor. Mol. Pharmacol. 57 (2000) 890-898
21. 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J. 15 (1996) 3566-3578
22. 1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 808-813
23. Gaborik Z., et al. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 144 (2003) 2220-2228
24. Yao X., et al. Coupling ligand structure to specific conformational switches in the β2-adrenoceptor. Nat. Chem. Biol. 2 (2006) 417-422
25. Farrens D.L., et al. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996) 768-770
26. 2 adrenoceptor function. Evidence for protonation-dependent activation. J. Biol. Chem. 275 (2000) 3121-3127
27. Samama P., et al. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
28. 1-adrenoceptor. Mol. Pharmacol. 62 (2002) 747-755
29. Petaja-Repo U.E., et al. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J. 21 (2002) 1628-1637
30. Balmforth A.J., et al. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J. Biol. Chem. 272 (1997) 4245-4251
31. Groblewski T., et al. Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J. Biol. Chem. 272 (1997) 1822-1826
32. Noda K., et al. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 (1996) 16435-16442
33. 2 Adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277 (2002) 40989-40996
34. 2 adrenoceptor: kinetic evidence for intermediate conformational states. J. Biol. Chem. 279 (2004) 686-691
35. Swaminath G., et al. Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280 (2005) 22165-22171
36. 2 adrenergic receptor. Mol. Pharmacol. 65 (2004) 1181-1190
37. 2 adrenergic receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5997-6002
38. 2 adrenergic receptor. J. Biol. Chem. 276 (2001) 24433-24436
39. Palanche T., et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276 (2001) 34853-34861
40. Kobilka B. Agonist binding: a multistep process. Mol. Pharmacol. 65 (2004) 1060-1062